New hope for kids with rare kidney disease: telitacicept vs. steroids
NCT ID NCT07354503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the drug telitacicept works better than standard steroids for children aged 3-17 with kidney inflammation caused by IgA vasculitis. About 300 participants will be followed for up to 48 weeks to see if their urine protein levels drop and kidney function stays stable. The goal is to give doctors a safer, more effective treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may spot hidden gut trouble in kids with rare disease
- New combo therapy aims to tame rare blood vessel disease
- Pregnancy and vasculitis: new study seeks answers
- Skin biopsies shed light on rare blood vessel disease
- Which drug tames skin vasculitis best? new trial aims to find out
- Scientists build tissue bank to unlock vasculitis mysteries